NO20054969L - 2-cyanopropansyreamid- og esterderivater og deres anvendelse - Google Patents

2-cyanopropansyreamid- og esterderivater og deres anvendelse

Info

Publication number: NO20054969L
Authority: NO; Norway
Prior art keywords: acid amide; ester derivatives; cyanopropanoic acid; treatment; diseases
Prior art date: 2003-04-30

Application number

NO20054969A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054969D0 (no

Inventor

Thomas Joseph Caggiano

William Jay Moore

Antony A Brazzale

Callain Younghee Kim

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-30

Filing date

2005-10-26

Publication date

2005-11-22

2005-10-26 Application filed by Wyeth Corp filed Critical Wyeth Corp

2005-10-26 Publication of NO20054969D0 publication Critical patent/NO20054969D0/no

2005-11-22 Publication of NO20054969L publication Critical patent/NO20054969L/no

Links

DASYJICSSLWYAG-UHFFFAOYSA-N 2-cyanopropanamide Chemical class N#CC(C)C(N)=O DASYJICSSLWYAG-UHFFFAOYSA-N 0.000 title 1
150000002148 esters Chemical class 0.000 title 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)

NO20054969A 2003-04-30 2005-10-26 2-cyanopropansyreamid- og esterderivater og deres anvendelse NO20054969L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46656703P	2003-04-30	2003-04-30
US10/833,678 US20050004164A1 (en)	2003-04-30	2004-04-28	2-Cyanopropanoic acid amide and ester derivatives and methods of their use
PCT/US2004/013360 WO2004099150A2 (en)	2003-04-30	2004-04-30	3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands

Publications (2)

Publication Number	Publication Date
NO20054969D0 NO20054969D0 (no)	2005-10-26
NO20054969L true NO20054969L (no)	2005-11-22

Family

ID=33436706

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054969A NO20054969L (no)	2003-04-30	2005-10-26	2-cyanopropansyreamid- og esterderivater og deres anvendelse

Country Status (17)

Country	Link
US (2)	US20050004164A1 (de)
EP (1)	EP1620102B1 (de)
JP (1)	JP2006526630A (de)
KR (1)	KR20060015556A (de)
AR (1)	AR044762A1 (de)
AT (1)	ATE418335T1 (de)
AU (1)	AU2004236216A1 (de)
BR (1)	BRPI0409921A (de)
CA (1)	CA2523235A1 (de)
CO (1)	CO5700755A2 (de)
CR (1)	CR8041A (de)
DE (1)	DE602004018629D1 (de)
MX (1)	MXPA05011581A (de)
NO (1)	NO20054969L (de)
RU (1)	RU2005137175A (de)
TW (1)	TW200508217A (de)
WO (1)	WO2004099150A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904724D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
SE9904723D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
US7544350B2 (en)	2002-11-22	2009-06-09	Hallstar Innovations Corp.	Method of decreasing the UV light degradation of polymers
BRPI0511907A8 (pt) *	2004-06-08	2018-05-02	A Carlsson Res Ab	novos derivados de fenilpiperidinas/piperazinas dissubstituídos como moduladores da neurotransmissão de dopamina
MXPA06013944A (es)	2004-06-08	2007-10-08	Neurosearch Sweden Ab	Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
US7851629B2 (en)	2004-06-08	2010-12-14	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
WO2005123663A1 (en) *	2004-06-14	2005-12-29	Wyeth	Processes for the preparation of 2-cyano-3-naphthalene-1-yl-3-phenyl-propionic acid alkyl or benzyl esters
US8685924B2 (en)	2004-08-25	2014-04-01	Takeda Pharmaceutical Company Limited	Preventives/remedies for stress urinary incontinence and method of screening the same
CN101056854B (zh)	2004-10-13	2013-06-05	Nsab神经研究瑞典公司分公司	合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
CN100562514C (zh) *	2005-07-22	2009-11-25	中国科学院上海药物研究所	一类取代丙酰胺衍生物、其制备方法和用途
SE529246C2 (sv)	2005-10-13	2007-06-12	Neurosearch Sweden Ab	Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
RU2303597C1 (ru) *	2006-05-12	2007-07-27	Иващенко Андрей Александрович	Фармацевтическая композиция, способы ее получения и применения
EP2727585A1 (de)	2006-05-16	2014-05-07	Takeda Pharmaceutical Company Limited	In-vivo Screening-Methode
EP2089355A2 (de) *	2006-11-01	2009-08-19	Brystol-Myers Squibb Company	Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung
EP2789338A3 (de)	2007-11-15	2015-01-14	Takeda Pharmaceutical Company Limited	Kondensiertes Pyridinderivat und seine Verwendung
EP2510949A4 (de)	2009-12-11	2013-11-13	Astellas Pharma Inc	Therapeutikum für fibromyalgie
US9365612B2 (en)	2010-01-29	2016-06-14	United States Of America As Represented By The Secretary, Department Of Health And Human Services	Caspase inhibitors
WO2011112263A1 (en) *	2010-03-11	2011-09-15	New York University	AMIDO COMPOUNDS AS RORγt MODULATORS AND USES THEREOF
US9765063B2 (en) *	2011-09-09	2017-09-19	New York University	Amido compounds as RORγt modulators and uses thereof
UY34503A (es)	2011-12-08	2013-07-31	Ivax Int Gmbh	?sal de bromhidrato de pridopidina?
KR20150013476A (ko)	2012-04-04	2015-02-05	아이백스 인터내셔널 게엠베하	조합요법용 약학적 조성물
IN2014DN09937A (de)	2012-05-30	2015-08-14	Clariant Int Ltd
US10813862B2 (en)	2012-05-30	2020-10-27	Clariant International Ltd.	Use of N-methyl-N-acylglucamines as solubilizers
DE102012021647A1 (de)	2012-11-03	2014-05-08	Clariant International Ltd.	Wässrige Adjuvant-Zusammensetzungen
TN2015000516A1 (en)	2013-05-28	2017-04-06	Astrazeneca Ab	Chemical compounds
DE202014008418U1 (de)	2014-02-19	2014-11-14	Clariant International Ltd.	Schaumarme agrochemische Zusammensetzungen
DE102014005771A1 (de)	2014-04-23	2015-10-29	Clariant International Ltd.	Verwendung von wässrigen driftreduzierenden Zusammensetzungen
DE202015008045U1 (de)	2015-10-09	2015-12-09	Clariant International Ltd.	Universelle Pigmentdispersionen auf Basis von N-Alkylglukaminen
DE102015219651A1 (de)	2015-10-09	2017-04-13	Clariant International Ltd.	Zusammensetzungen enthaltend Zuckeramin und Fettsäure
DE202016003070U1 (de)	2016-05-09	2016-06-07	Clariant International Ltd.	Stabilisatoren für Silikatfarben
KR101828241B1 (ko) *	2016-10-17	2018-02-13	(주)네오팜	항염용 조성물
KR101828240B1 (ko)	2016-10-17	2018-02-13	(주)네오팜	항염용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6451817B1 (en) *	1995-03-10	2002-09-17	Eli Lilly And Company	Alpha-substituted-1-benzyl-napthyls
DE69739181D1 (de) *	1996-08-12	2009-02-05	Celgene Corp	Neue immunotherapeutische Mittel und deren Verwendung in der Reduzierung von Cytokinenspiegel
DE69814618T2 (de) *	1997-02-15	2004-03-25	Millenium Pharmaceuticals, Inc., Cambridge	Behandlung von infarkten durch inhibierung von nf-kappab
CA2298651A1 (en) *	1997-08-07	1999-02-18	Jeffrey Alan Dodge	1-¬4-(substituted alkoxy)benzyl\|naphthalene compounds having estrogen inhibitory activity
JPH11295383A (ja) *	1998-04-15	1999-10-29	Mitsubishi Electric Corp	マイクロ波帯域用半導体トランジスタのバーンイン方法、バーンイン装置及びバーンインした半導体装置
HUP0102782A3 (en) *	1998-06-19	2002-12-28	Smithkline Beecham Corp	Salycilanilide as inhibitors of transcription factor nf-kb
PL206826B1 (pl) *	1999-06-23	2010-09-30	Sanofi Aventis Deutschland	Podstawione benzimidazole
DE19951360A1 (de) *	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
WO2005039582A1 (en) *	2003-09-24	2005-05-06	Wyeth	METHODS OF TREATING ATHEROSCLEROSIS USING NF-kB INHIBITORS
AU2003272675A1 (en) *	2003-09-24	2005-05-11	Wyeth	Use of estrogen receptor ligands for the treatment of inflammatory bowel disease
WO2005039583A1 (en) *	2003-09-24	2005-05-06	Wyeth	METHOD OF TREATING RHEUMATOID ARTHRITIS USING NF-kB INHIBITORS

2004
- 2004-04-28 US US10/833,678 patent/US20050004164A1/en not_active Abandoned
- 2004-04-29 TW TW093111996A patent/TW200508217A/zh unknown
- 2004-04-30 AT AT04750987T patent/ATE418335T1/de not_active IP Right Cessation
- 2004-04-30 BR BRPI0409921-4A patent/BRPI0409921A/pt not_active IP Right Cessation
- 2004-04-30 EP EP04750987A patent/EP1620102B1/de not_active Expired - Lifetime
- 2004-04-30 KR KR1020057020599A patent/KR20060015556A/ko not_active Withdrawn
- 2004-04-30 JP JP2006514164A patent/JP2006526630A/ja active Pending
- 2004-04-30 CA CA002523235A patent/CA2523235A1/en not_active Abandoned
- 2004-04-30 RU RU2005137175/04A patent/RU2005137175A/ru not_active Application Discontinuation
- 2004-04-30 DE DE602004018629T patent/DE602004018629D1/de not_active Expired - Fee Related
- 2004-04-30 AU AU2004236216A patent/AU2004236216A1/en not_active Abandoned
- 2004-04-30 WO PCT/US2004/013360 patent/WO2004099150A2/en not_active Ceased
- 2004-04-30 AR ARP040101492A patent/AR044762A1/es unknown
- 2004-04-30 MX MXPA05011581A patent/MXPA05011581A/es not_active Application Discontinuation
2005
- 2005-10-12 CR CR8041A patent/CR8041A/es not_active Application Discontinuation
- 2005-10-26 NO NO20054969A patent/NO20054969L/no not_active Application Discontinuation
- 2005-10-26 CO CO05109228A patent/CO5700755A2/es not_active Application Discontinuation
2007
- 2007-07-31 US US11/831,375 patent/US20070299105A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CO5700755A2 (es)	2006-11-30
AR044762A1 (es)	2005-10-05
BRPI0409921A (pt)	2006-04-25
RU2005137175A (ru)	2006-05-27
TW200508217A (en)	2005-03-01
MXPA05011581A (es)	2005-12-14
WO2004099150A2 (en)	2004-11-18
EP1620102A2 (de)	2006-02-01
KR20060015556A (ko)	2006-02-17
ATE418335T1 (de)	2009-01-15
CA2523235A1 (en)	2004-11-18
NO20054969D0 (no)	2005-10-26
WO2004099150A3 (en)	2004-12-23
CR8041A (es)	2006-05-30
JP2006526630A (ja)	2006-11-24
DE602004018629D1 (de)	2009-02-05
US20050004164A1 (en)	2005-01-06
AU2004236216A1 (en)	2004-11-18
US20070299105A1 (en)	2007-12-27
EP1620102B1 (de)	2008-12-24

Legal Events

Date	Code	Title	Description
2007-11-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20054969L (no)	2005-11-22	2-cyanopropansyreamid- og esterderivater og deres anvendelse
NO20051942L (no)	2005-06-14	Substituerte 4-cindazol-3-yl)fenoler som ostrogenreseptor-(ER) ligander og deres anvendelse ved behandling av inflammatoriske sykdommer
ATE370934T1 (de)	2007-09-15	Substituierte dihydrophenanthridin-sulfonamide
NO20053627L (no)	2005-08-10	Malonamidderivater som gamma-sekretase inhibitorer
WO2006124490A3 (en)	2007-03-08	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NO20070893L (no)	2007-04-13	Hydantoinderivater for behandling av inflammasjonslidelser.
EA200700711A1 (ru)	2008-02-28	Производные бензимидазолуксусной кислоты, проявляющие антагонизм в отношении рецептора crth2, и их применение
NO20070994L (no)	2007-04-26	N-hydroksamid derivater og anvendelse derav
NO20043900L (no)	2004-11-10	Heterocykliske forbindelser som inhiberer leukocyttadhesjon formidlet av integriner
DE69912581D1 (de)	2003-12-11	Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DE602004008098D1 (de)	2007-09-20	Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
HK1050008A1 (zh)	2003-06-06	杂双环磺胺剂及以其作为血小板腺苷二磷酸(adp)受体抑制剂
NO20064151L (no)	2006-11-06	Nye forbindelser
NO20055305D0 (no)	2005-11-10	Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase
NO20055568L (no)	2006-01-20	Substituerte 1,4-diazepiner og anvendelser derav
DOP2003000678A (es)	2004-02-15	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
NO20071658L (no)	2007-05-03	Alkil-pyridiner som 11-beta-inhibitorer for diabetes
PT1406898E (pt)	2005-08-31	Compostos de piperazina substituida e sua utilizacao como inibidores de oxidacao de acidos gordos
NO20052487L (no)	2005-05-24	1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.
TW200612965A (en)	2006-05-01	Methods for preparing p2x7 inhibitors
NO20076396L (no)	2008-02-01	Substituert akrylamidderivat og farmasoytisk preparat som omfatter dette
NO20070820L (no)	2007-02-13	Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav.
NO20080860L (no)	2008-04-18	Substituert propanamidderivat og farmasoytisk preparat som inneholder dette
NO20055752L (no)	2006-01-09	N-ureidoalkyl-piperidiner som modulerer forbindelser av kjemokinreseptor-aktivitet
ATE443058T1 (de)	2009-10-15	Substituierte heterozyklische verbindungen